@article{discovery10184141,
       publisher = {Elsevier BV},
           title = {Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity},
            year = {2021},
         journal = {Clinical Infection in Practice},
          volume = {12},
           month = {November},
            note = {{\copyright} 2021 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association. This is an open access article under the CC BY-NC-ND.},
             url = {https://doi.org/10.1016/j.clinpr.2021.100089},
            issn = {2590-1702},
        abstract = {Background: The role of antibodies in coronavirus disease 2019 (COVID-19) in patients with X-linked agammaglobulinaemia (XLA) has yet to be characterised and clinical courses observed in this cohort of patients have been heterogeneous. Whilst some exhibit spontaneous recovery, others have experienced a more protracted disease length. Previous reports have described successful use of convalescent plasma, however there is a paucity of information around the use of the REGN-COV2 antibody cocktail in these patients. Case report: A patient with XLA was admitted to hospital with COVID-19 and remained persistently symptomatic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swab positivity despite treatment with Remdesivir and dexamethasone. Attempts at modulating the immune response with anakinra were unsuccessful. Consent for compassionate use of REGN-COV2 was obtained with administration taking place on day 87 of his illness. This was followed by a period of convalescence and SARS-CoV-2 nasopharyngeal swab negativity. As a consequence of prolonged immunosuppression, the patient developed pneumocystis pneumonia. Conclusion: This case highlights the role of antibodies in clearing SARS-CoV-2 in a hypogammaglobulinaemic host and demonstrates the consequences of prolonged immunosuppression and delayed treatment. We propose that this may be of particular significance given the capacity of SARS-CoV-2 to develop advantageous mutations in a chronically infected host.},
          author = {Nguyen, H and Salkeld, J and Agarwal, S and Goodman, A},
        keywords = {Agammaglobulinemia, COVID-19, REGN-COV2, Remdesivir, SARS-CoV2}
}